Mediterrania leads investment in Moroccan pharmaceutical company

Mediterrania Capital Partners (MCP), a private equity firm that focuses on growth investments in small and mid-sized African companies, recently led a consortium that invested in Laprophan, a pharmaceuticals company in Morocco.

The consortium, which included Proparco, FMO, and DEG, provided a capital increase of MDH 750 million (approximately $72.1 million) to acquire a minority stake in Laprophan.

The investment is still pending approval from the Moroccan Competition Council. If approved, the capital increase will allow Laprophan to expand its business and strength its position in both domestic and international markets. 

Asafo & Co., a law firm, advised MCP on the investment in Laprophan and the co-investment arrangements with the other consortium members.